NantOmics and NantHealth Announce Results of Proprietary Machine Vision AI Software Study Demonstrating the Ability to Identify Aggressive Subtypes of Breast Cancer from Digital Pathology Images

by Jen Hodson | Feb 19, 2020 | Press Releases

Study Published In Breast Cancer Research Shows How Deep-Learning Of Over 650 Breast Cancer Digital Pathology Images And Omics Data Can Be Used Together To Unlock Precise Mechanisms Of Therapy Resistance Culver City, CA – February 19, 2020: NantOmics, LLC, the leader...

NantHealth and NantOmics Announce GPS Cancer® Platform May Improve Clinical Trial Design of Combination Strategies by Identifying Previously Unrecognized Cancer Type Specific Associations between Immunoregulatory Molecules and Genomic Mutations

by Jen Hodson | Feb 19, 2020 | Press Releases

Findings Presented at the ASCO-SITC 2020 Clinical Immuno-Oncology Symposium Orlando, FL and Culver City, CA – February 6, 2020 – NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company and NantOmics, LLC, the leader in...

NantHealth and NantOmics Reveal a Novel AI Based Machine-Learning Digital Pathology Software for Lung Cancer by Identifying Tumor Infiltrating Killer Cells from Whole Slide Images

by Jen Hodson | Jan 29, 2020 | Press Releases

Derived from deep-learning models, the findings demonstrate novel AI methods of identifying tumor-infiltrating lymphocytes (TILs) in lung cancers Burlingame, CA – January 28, 2020: NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized...

NantKwest, NantCell and NantOmics to Provide Updated Preclinical and Clinical Data in Four Abstracts at Part of the American Society of Clinical Oncology Annual Meeting

by Jen Hodson | May 31, 2019 | Press Releases

Preclinical and Clinical Data Demonstrate Advanced Deployment of Precision Medicine Tools to Analyze and Potentially More Effectively Intervene with Highly Focused Therapeutic Interventions Culver City, May 31, 2019 – NantKwest (Nasdaq:NK), a leading clinical-stage,...

NantHealth® and NantOmics to Reveal New Research Demonstrating Importance of Examining RNA Expression and Individual Biomarkers in Cancer Testing

by Jen Hodson | Feb 14, 2019 | Press Releases

Findings to be presented at the 2019 American Society of Clinical Oncology’s Genitourinary Cancers Symposium San Francisco and Culver City, CA – February 14, 2019 – Scientific teams from NantHealth (NASDAQ: NH) and NantOmics will present two posters at the American...

NantHealth and NantOmics Present Four Research Papers Demonstrating Advancements in Cancer Diagnostics with NantHealth’s GPS Cancer® and Liquid GPS™

by Jen Hodson | Oct 29, 2018 | Press Releases

NantHealth’s Liquid GPS™ technology shows promise in the monitoring of key biomarkers in metastatic colorectal cancer  MUNICH and CULVER CITY, CA – (October 29, 2018) — Significant developments in cancer research were presented by NantHealth...